Medicine in black and white: BiDil®: race and the limits of evidence-based medicine
Article first published online: 23 AUG 2006
Volume 3, Issue 3, pages 118–121, September 2006
How to Cite
Ellison, G. (2006), Medicine in black and white: BiDil®: race and the limits of evidence-based medicine. Significance, 3: 118–121. doi: 10.1111/j.1740-9713.2006.00181.x
- Issue published online: 23 AUG 2006
- Article first published online: 23 AUG 2006
When the US Food and Drug Administration licensed the drug BiDil® in June 2005 it was hailed as a significant step towards “personalised prescribing”. This is because BiDil® had been patented, tested and approved for use by just one group of patients: those “of African descent”. George Ellison examines the statistical evidence that underpinned the development of BiDil® as a “racial drug” and finds it less than satisfactory.